AI Article Synopsis
- The study examined how different factors impact the survival of patients with stage IV gastric cancer receiving chemotherapy.
- Patients treated with S-1 therapy had a significantly longer median survival time (429 days) compared to those who did not receive S-1 therapy (236 days).
- Better survival rates were associated with having good performance status, having only one metastatic site, and receiving second-line chemotherapy, though few patients with multiple metastatic sites could access second-line options.
- Overall, while S-1 therapy improved outcomes, patients with multiple metastases still faced poor prognosis, highlighting the need for more effective treatments for this group.
Article Abstract
Background: We retrospectively analyzed the influence of various clinicopathologic factors on the survival of patients treated with chemotherapy.
Methods: A retrospective analysis was made of 110 patients with stage IV gastric cancer who were treated from January 1996 to June 2004.
Results: Median survival time was 429 days for patients treated with S-1 therapy and 236 days for patients without S-1 therapy. A better survival was demonstrated in patients who had good performance status, one metastatic site, or had been given a second-line chemotherapy (P < 0.01). But very few patients (17%; 5/29) with multiple metastatic sites were able to receive the second-line chemotherapy.
Conclusion: Patients treated with S-1 therapy had a better prognosis than patients without S-1. One metastatic site and being given second-line chemotherapy were other factors for better prognosis. For patients with only one metastatic site, a good prognosis can be obtained by second-line chemotherapy for those refractory to S-1. The prognosis of patients who had more than two metastatic sites remained poor; more effective chemotherapy might improve the survival of such patients if they retain good performance status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10147-006-0588-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Versatile Thermally Activated Delayed Fluorescence Material Enabling High Efficiencies in both Photodynamic Therapy and Deep-Red/NIR Electroluminescence.
ACS Nano
January 2025
Institute of Functional Nano & Soft Materials (FUNSOM), Joint International Research Laboratory of Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, Jiangsu, China.
Thermally activated delayed fluorescence (TADF) materials have received increasing attention from organic electronics to other related fields, such as bioapplications and photocatalysts. However, it remains a challenging task for TADF emitters to showcase the versatility concurrent with high performance in multiple applications. Herein, we first present such a proof-of-concept TADF material, namely, QCN-SAC, through strategically manipulating exciton dynamics.
View Article and Find Full Text PDFAged garlic extract enhances the production of β‑defensin 4 via activation of the Wnt/β‑catenin pathway in mouse gingiva.
Exp Ther Med
February 2025
Central Research Institute, Wakunaga Pharmaceutical Co., Ltd., Akitakata, Hiroshima 739-1195, Japan.
Periodontal disease is recognized as a chronic multifactorial inflammatory condition initiated by dysbiosis within subgingival plaque biofilms. Antimicrobial peptides exhibit a wide spectrum of antimicrobial action, and thus, provide one of the first lines of host defense against oral pathogens. Aged garlic extract (AGE) is effective for preventing the progression of periodontal disease.
View Article and Find Full Text PDFAutomatically optimized vectorcardiographic features are associated with recurrence of atrial fibrillation after electrical cardioversion.
Sci Rep
January 2025
Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Electrical cardioversion presents one of the treatment options for atrial fibrillation (AF). However, the early recurrence rate is high, reaching ~40% three months after the procedure. Features based on vectorcardiographic signals were explored to find association with early recurrence of AF.
View Article and Find Full Text PDFAssessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.
Jpn J Clin Oncol
January 2025
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer.
View Article and Find Full Text PDFHighly efficient metal-free electrochemical membrane enables zero-valent sulfur recovery from thiourea wastewater.
Water Res
January 2025
School of Science, RMlT University, Melbourne, VC 3000. Australia.
Electrochemical recovery of zero-valent sulfur (S) from thiourea (TU) wastewater offers a promising waste-to-value strategy that expects to promote the sulfur resource cycle in water treatment but still suffer from electrode poisoning and sulfur over-oxidation. Herein, we designed a metal-free CNT electrochemical membrane for selective oxidation of thiourea and recovery of S. We found that defect sites on the carbon nanotube surface enable direct electron transfer for thiourea oxidation and may form carbon-sulfur bridge bonds, thereby facilitating the generation of S and urea.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!